ABT

Ken Griffin's Citadel significantly increased positions in healthcare stocks during Q2, boosting AbbVie by 546%, Abbott Laboratories by 349%, and Eli Lilly by 291%. The moves suggest Griffin is seeking defensive, dividend-yielding stocks amid anticipated market volatility. AbbVie, a Dividend King with 54 consecutive years of dividend increases, is highlighted as a strong buy with attractive valuation and solid earnings growth.

The article recommends two Dividend King healthcare stocks for passive income: Abbott Laboratories and Johnson & Johnson. Both companies have demonstrated 50+ years of consecutive dividend increases, strong free cash flow, diversified business portfolios, and solid growth prospects. Abbott offers a 2.5% dividend yield with innovative products like the Libre Duo glucose monitor, while J&J pays a 2% yield and is positioned to reach $100 billion in annual revenue with a strong oncology pipeline.

Abbott (ABT) closed at $101.82, up 2.23%, outperforming the S&P 500's 0.06% decline. The company is expected to report Q3 earnings on October 21, 2026, with projected EPS of $1.42 (up 9.23% YoY) and revenue of $12.91 billion (up 13.52% YoY). Abbott holds a Zacks Rank #2 (Buy) rating and trades at a Forward P/E of 18.04, below its industry average of 19.61.